- Anthracyclines
- Antimetabolites
- Epothilones
- Taxanes
- Alkylating agents
- Hormonal therapy
- Aromatase inhibitors
- Selective Oestrogen-receptor modulators
Breast Cancer Treatment Market size was valued at USD 33.20 billion in 2022, growing at a CAGR of 7.9% from 2023-29. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease. In July 2017, U.S. FDA Approved Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stag. In July 2017, AstraZeneca received the approval from European Commission (EC) for  Faslodex (fulvestrant) for the breast cancer treatment
Global Breast Cancer Treatment Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.9%
Largest Market
North America
Fastest Growing Market
Europe
Breast Cancer Treatment Market Dynamics
The global breast cancer treatment market is expected to increase with significant CAGR due to increasing prevalence and incidence of breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Moreover, the rise in the healthcare expenditure, increase in the diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco, and rising female population age of 65 years and above are expected to fuel the market over the forecast period. Furthermore, increase in the investments in research and developments, development of targeted drug delivery systems, and advancement in cancer biology & pharmacology might boost the market. However, drug development challenges in developing countries, long-term side effects of drugs, high costs associated with drug development, stringent regulatory guidelines, and patent expiry of drugs might hamper the growth of the market in the forecast years.
Breast Cancer Treatment Market Regional Analysis
North-America Got Significant Share
Geographically, the breast cancer drugs market segmented into following regions Viz. Europe, Latin America, Middle East and Africa, Asia-Pacific, and North America. North America dominates the breast cancer treatment market mainly attributed to high prevalence of breast cancer disease, increase in female aging population, and favourable government initiatives for the treatment. Furthermore, increase in the healthcare infrastructure, favourable reimbursement policies, and high incorporation of targeted therapies also propel the breast cancer treatment market growth in North America region. Europe holds a major share in breast cancer treatment market owing to rise in the prevalence and incidence of breast cancer cases (According to World Cancer Research Fund International, nearly 1.7 million new breast cancer cases were diagnosedin 2012. In the UK itself, 53,696 new cases were diagnosed in 2013).
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Breast Cancer Treatment Market Segmentation
By Drug Class
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Latin Americ
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Breast Cancer Treatment Market Introduction |
| 2.1. Global Breast Cancer Treatment Market – Taxonomy |
| 2.2. Global Breast Cancer Treatment Market –Definitions |
| 2.2.1. By Treatment |
| 2.2.2. By Cancer Type |
| 2.2.3. By Distribution Channel |
| 3. Global Breast Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Breast Cancer Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Breast Cancer Treatment Market – Competition Landscape |
| 4. Global Breast Cancer Treatment Market Analysis,2017 - 2021 and Forecast, 2022 - 2028 |
| 2.1. Global Breast Cancer Treatment Market – Taxonomy |
| 2.1. Global Breast Cancer Treatment Market – Taxonomy |
| 2.1. Global Breast Cancer Treatment Market – Taxonomy |
| 5. Global Breast Cancer Treatment Market, By Treatment, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)Â |
| 5.1. Immunotherapy |
| 5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Chemotherapy |
| 5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Targeted Treatment |
| 5.3.1. Abemaciclib |
| 5.3.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.1.3. Market Opportunity Analysis |
| 5.3.2. Ado-Trastuzumab Emtansine |
| 5.3.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.2.3. Market Opportunity Analysis |
| 5.3.3. Everolimus |
| 5.3.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3.3. Market Opportunity Analysis |
| 5.3.4. Olaparib |
| 5.3.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.4.3. Market Opportunity Analysis |
| 5.3.5. Palbociclib |
| 5.3.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.5.3 Market Opportunity Analysis |
| 5.3.6. Pertuzumab |
| 5.3.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.6.3. Market Opportunity Analysis |
| 5.3.7. Ribociclib |
| 5.3.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.7.3. Market Opportunity Analysis |
| 5.3.8. Trastuzumab |
| 5.3.8.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.8.3. Market Opportunity Analysis |
| 5.3.9. Others |
| 5.3.9.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.9.3. Market Opportunity Analysis |
| 5.4. Hormonal Treatment |
| 5.4.1. Aromatase Inhibitors |
| 5.4.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.1.3. Market Opportunity Analysis |
| 5.4.2. Estrogen Receptor Downregulators (ERDs) |
| 5.4.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.2.3. Market Opportunity Analysis |
| 5.4.3. Selective Estrogen Receptor Modulators (SERMs) |
| 5.4.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3.3. Market Opportunity Analysis |
| 6. Global Breast Cancer Treatment Market Forecast, By Cancer Type, 2017 - 2021 and Forecast, 2020 – 2026 (Revenue, USD Mn) |
| 6.1. HER2+ |
| 6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Hormone Receptor |
| 6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Breast Cancer Treatment Market Forecast, By Distribution Channel, 2017 - 2021 and Forecast, 2020 – 2026 (Revenue, USD Mn) |
| 7.1. Hospital |
| 7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Pharmacies |
| 7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Breast Cancer Treatment Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)Â |
| 8.1. North America |
| 8.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Region, 2022 - 2028 |
| 9. North America Breast Cancer TreatmentMarketAnalysis,2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)Â |
| 9.1. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Flat Rolled |
| 9.1.2. Immunotherapy |
| 9.1.3. Chemotherapy |
| 9.1.4. Targeted Treatment |
| 9.1.4.1. Abemaciclib |
| 9.1.4.2. Ado-Trastuzumab Emtansine |
| 9.1.4.3. Everolimus |
| 9.1.4.4. Trastuzumab |
| 9.1.4.5. Ribociclib |
| 9.1.4.6. Palbociclib |
| 9.1.4.7. Pertuzumab |
| 9.1.4.8. Olaparib |
| 9.1.4.9. Others |
| 9.1.5. Hormonal Treatment |
| 9.1.5.1. Aromatase Inhibitors |
| 9.1.5.2. Estrogen Receptor Downregulators (ERDs) |
| 9.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
| 9.2. Cancer Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. HER2+ |
| 9.2.2. Hormone Receptor |
| 9.3. Distribution Channel Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Hospital |
| 9.3.2. Retail Pharmacies |
| 9.3.3. Online Pharmacies |
| 9.3.4. Pharmacies |
| 9.3.5. Others |
| 9.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country, 2022 - 2028 |
| 9.6. North America Breast Cancer Treatment Market Dynamics – Trends |
| 10. Europe Breast Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)Â |
| 10.1. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Flat Rolled |
| 10.1.2. Immunotherapy |
| 10.1.3. Chemotherapy |
| 10.1.4. Targeted Treatment |
| 10.1.4.1. Abemaciclib |
| 10.1.4.2. Ado-Trastuzumab Emtansine |
| 10.1.4.3. Everolimus |
| 10.1.4.4. Trastuzumab |
| 10.1.4.5. Ribociclib |
| 10.1.4.6. Palbociclib |
| 10.1.4.7. Pertuzumab |
| 10.1.4.8. Olaparib |
| 10.1.4.9. Others |
| 10.1.5. Hormonal Treatment |
| 10.1.5.1. Aromatase Inhibitors |
| 10.1.5.2. Estrogen Receptor Downregulators (ERDs) |
| 10.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
| 10.2. Cancer Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. HER2+ |
| 10.2.2. Hormone Receptor |
| 10.3. Distribution Channel Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Hospital |
| 10.3.2. Retail Pharmacies |
| 10.3.3. Online Pharmacies |
| 10.3.4. Pharmacies |
| 10.3.5. Others |
| 10.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 - 2028 |
| 10.6. Europe Breast Cancer Treatment Market Dynamics – Trends |
| 11. Asia-Pacific Breast Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 11.1. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Flat Rolled |
| 11.1.2. Immunotherapy |
| 11.1.3. Chemotherapy |
| 11.1.4. Targeted Treatment |
| 11.1.4.1. Abemaciclib |
| 11.1.4.2. Ado-Trastuzumab Emtansine |
| 11.1.4.3. Everolimus |
| 11.1.4.4. Trastuzumab |
| 11.1.4.5. Ribociclib |
| 11.1.4.6. Palbociclib |
| 11.1.4.7. Pertuzumab |
| 11.1.4.8. Olaparib |
| 11.1.4.9. Others |
| 11.1.5. Hormonal Treatment |
| 11.1.5.1. Aromatase Inhibitors |
| 11.1.5.2. Estrogen Receptor Downregulators (ERDs) |
| 11.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
| 11.2. Cancer Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. HER2+ |
| 11.2.2. Hormone Receptor |
| 11.3. Distribution Channel Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Hospital |
| 11.3.2. Retail Pharmacies |
| 11.3.3. Online Pharmacies |
| 11.3.4. Pharmacies |
| 11.3.5. Others |
| 11.4. Country Analysis2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 - 2028 |
| 11.6. Asia-Pacific Breast Cancer Treatment Market Dynamics – Trends |
| 12. Latin America Breast Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 12.1. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Flat Rolled |
| 12.1.2. Immunotherapy |
| 12.1.3. Chemotherapy |
| 12.1.4. Targeted Treatment |
| 12.1.4.1. Abemaciclib |
| 12.1.4.2. Ado-Trastuzumab Emtansine |
| 12.1.4.3. Everolimus |
| 12.1.4.4. Trastuzumab |
| 12.1.4.5. Ribociclib |
| 12.1.4.6. Palbociclib |
| 12.1.4.7. Pertuzumab |
| 12.1.4.8. Olaparib |
| 12.1.4.9. Others |
| 12.1.5. Hormonal Treatment |
| 12.1.5.1. Aromatase Inhibitors |
| 12.1.5.2. Estrogen Receptor Downregulators (ERDs) |
| 12.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
| 12.2. Cancer Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. HER2+ |
| 12.2.2. Hormone Receptor |
| 12.3. Distribution Channel Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Hospital |
| 12.3.2. Retail Pharmacies |
| 12.3.3. Online Pharmacies |
| 12.3.4. Pharmacies |
| 12.3.5. Others |
| 12.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 - 2028 |
| 12.6. Latin America Breast Cancer Treatment Market Dynamics – Trends |
| 13. Middle East and Africa Breast Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)Â |
| 13.1. Treatment Analysis 2017 - 2021 and Forecast 2022 - 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Flat Rolled |
| 13.1.2. Immunotherapy |
| 13.1.3. Chemotherapy |
| 13.1.4. Targeted Treatment |
| 13.1.4.1. Abemaciclib |
| 13.1.4.2. Ado-Trastuzumab Emtansine |
| 13.1.4.3. Everolimus |
| 13.1.4.4. Trastuzumab |
| 13.1.4.5. Ribociclib |
| 13.1.4.6. Palbociclib |
| 13.1.4.7. Pertuzumab |
| 13.1.4.8. Olaparib |
| 13.1.4.9. Others |
| 13.1.5. Hormonal Treatment |
| 13.1.5.1. Aromatase Inhibitors |
| 13.1.5.2. Estrogen Receptor Downregulators (ERDs) |
| 13.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
| 13.2. Cancer Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. HER2+ |
| 13.2.2. Hormone Receptor |
| 13.3. Distribution Channel Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Hospital |
| 13.3.2. Retail Pharmacies |
| 13.3.3. Online Pharmacies |
| 13.3.4. Pharmacies |
| 13.3.5. Others |
| 13.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 - 2028 |
| 13.6. MEA Breast Cancer Treatment Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Cancer Type& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. AstraZeneca plc |
| 14.2.2. Eisai Co. Ltd. |
| 14.2.3. Eli Lilly and Company |
| 14.2.4. F. Hoffmann-La Roche Ltd. |
| 14.2.5. GlaxoSmithKline plc |
| 14.2.6. Novartis International AG |
| 14.2.7. Pfizer Inc. |
| 14.2.8. Puma Biotechnology Inc. |
| 14.2.9. Sanofi S.A. |
| 14.2.10. Teva Pharmaceutical Industries Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- AstraZeneca (U.K.)
- GlaxoSmithKline plc (U.K.)
- Eli Lilly and Company (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer, Inc (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- Actavis, Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Teva Pharmaceutical Industries. Ltd. (Israel)
- Puma Biotechnology, Inc. (U.S.)
- OncoGenex Pharmaceuticals Inc. (U.S.)